Krystal Biotech, Inc.

KRYS Nasdaq CIK: 0001711279

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type operating
SEC Category Large accelerated filer
Business Address 2100 WHARTON STREET, PITTSBURGH, PA, 15203
Mailing Address 2100 WHARTON STREET, PITTSBURGH, PA, 15203
Phone (412) 586-5830
Fiscal Year End 1231
EIN 821080209

Financial Overview

FY2025

$1.33B
Total Assets
$522.23M
Stockholders' Equity
$496.30M
Cash & Equivalents
$7.08
EPS

Recent SEC Filings

Form Type Date Filed Document
SCHEDULE 13G/A Passive ownership amendment March 27, 2026 View on SEC
3 Initial insider ownership report March 6, 2026 View on SEC
3 Initial insider ownership report March 6, 2026 View on SEC
4 Insider stock transaction report March 6, 2026 View on SEC
4 Insider stock transaction report March 6, 2026 View on SEC
4 Insider stock transaction report March 3, 2026 View on SEC
4 Insider stock transaction report March 3, 2026 View on SEC
4 Insider stock transaction report March 3, 2026 View on SEC
4 Insider stock transaction report March 3, 2026 View on SEC
4 Insider stock transaction report February 26, 2026 View on SEC

Annual Reports

10-K February 17, 2026
  • Krystal Biotech achieved a substantial 160% revenue surge to $255 million in 2025, driven by the successful commercial launch of VYJUVEK®.
  • The company significantly narrowed its net loss to $115 million, an improvement from $180 million in the prior year.
View Analysis

Insider Trading

STRONG SELL 5 insiders 84 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.